INSM
Insmed Incorporated
NMS
$103.50
-0.23
(-0.22%)
Pullback · -1.64σ
Valuation
Market cap
$22.4B
P/E (ttm)
—
Forward P/E
256.2
Beta (5y)
0.89
Shares out
216.8M
Div yield
—
Profitability & returns
ROE
-294.5%
Net margin
-144.4%
FCF margin
-74.0%
Debt / equity
1.05
Trading information
Last price
$103.50
Day range
$103.50 – $103.50
52-wk range
$98.90 – $208.81
Avg volume
2.9M
RSI (2)
8.4
TAO zone
Pullback
Company
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Next earnings
2026-08-06
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen …